Fig. 7: Clinical trial of YL-13027 in three human SBC patients. | Cell Discovery

Fig. 7: Clinical trial of YL-13027 in three human SBC patients.

From: Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma

Fig. 7

a The chemical structure of YL-13027, a distinct chemical entity as a TGF-βR1 inhibitor. b The design of the phase I dose-escalation and dose-expansion study of YL-13027. The starting dose was 60 mg/day and then increased to 120, 180, 240, 300, and 360 mg/day. At each dosage over 120 mg/day, a cohort of 3–6 patients were enrolled, and the dose-limiting toxicities (DLTs) were evaluated within the first 4 weeks of drug administration. Three SBC patients were enrolled at a dose of 360 mg/day. No DLT was observed in these three patients. One patient experienced transient rash in both the knee and abdomen. c Diagram of SBC progression and treatment in three patients. The tumor was confirmed to recur locally and progressed rapidly. Up to the cutoff date, all patients achieved stable disease. d The tumor (Patient 1) was monitored by MRI evaluation. e SBC obviously progressed before enrollment and stabilized after the administration of YL-13027.

Back to article page